Iván González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:
“Exiting news! The long-awaited results from FLAURA2 phase III trial presented at WCLC2025 showing remarkable progress for patients with EGFR plus advanced NSCLC.
– Benefit: consistent across subgroups
– First line chemotherapy plus osimertinib improves overall survival from 37.6 to 47.5 months HR 0.77 vs, 48m OS rate 41% to 49% with osimertinib as monotherapy.”
More Posts Featuring Iván González.
